ERVE-1

Background:
Gene transfer is a new cancer therapy takes white blood cells from a person and grows them in a lab. The cells are changed with a virus to attack tumor cells, then returned to the person. Researchers want to see if this therapy fights kidney cancer cells.
Objective:
To see if gene transfer is safe and causes tumors to shrink.
Eligibility:
People at least 18 years old with certain kidney cancer
Design:
Participants will be screened with blood and urine tests. They may have:
* Scans
* Heart, lung, and eye tests
* Lab tests
* Tumor samples taken
Participants will have leukapheresis. Blood will be removed by a needle in an arm. It will go through a machine that removes white blood cells. Plasma and red cells will be returned through a needle in the participant s other arm.
Participants cells will be grown in the lab and genetically changed.
Participants will stay in the hospital 2-3 weeks. There they will:
* Get 2 chemotherapy drugs by catheter (thin plastic tube) inserted into a vein in the chest.
* Get the changed cells via catheter.
* Get a drug to increase white blood cell count and one to make the cells active.
* Recover for about a week.
* Have lab and blood tests.
After leaving the hospital, participants will:
* Take an antibiotic for several months.
* Have leukapheresis.
* Have one- or two-day clinic visits every few weeks for 2 years, and then as determined by their doctor. These will include blood and lab tests, imaging studies, and physical exam.
Participants will have follow-up checks for up to 15 years.